News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Amol Akhade Highlights ROSELLA trial Results on Relacorilant in Platinum-Resistant Ovarian Cancer
Amol Akhade/hiranandanihospital.org
Jun 20, 2025, 10:55

Amol Akhade Highlights ROSELLA trial Results on Relacorilant in Platinum-Resistant Ovarian Cancer

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:

“ROSELLA trial – ESMO GynaeCancer
Platinum-resistant ovarian cancer
Testing relacorilant (SGRA) + nab-paclitaxel vs nab-paclitaxel alone
MOA: Relacorilant = Selective Glucocorticoid Receptor Antagonist
Blocks cortisol’s anti-apoptotic effect
Potentiates chemo response without added toxicity
PFS (by BICR): 6.5 vs 5.5 mo | HR 0.70 | P = 0.0076
OS (interim): 16.0 vs 11.5 mo | HR 0.69 | P = 0.0121
12-mo OS: 60% vs 49%
 Benefit consistent in:
– Primary platinum-refractory
– 1–6 months platinum-free interval
– No biomarker required
– Well tolerated
– A first-in-class chemo sensitizer may be here!”

ROSELLA trial

More posts featuring Amol Akhade.

Amol Akhade cancer OncoDaily Oncology Relacorilant ROSELLA trial
Special Coverage
Opinion
Jun 20, 2025, 10:55
Amol Akhade Highlights ROSELLA trial Results on Relacorilant in Platinum-Resistant Ovarian Cancer
Blog
Jun 20, 2025, 10:49
Elvina Almuradova Shares Real-World NSCLC Treatment Outcomes Post Chemoimmunotherapy
Opinion
Jun 20, 2025, 10:48
Aaron Goodman: HMA-Venetoclax-Ivosidenib in Frontline AML
Blog
Jun 20, 2025, 10:42
Robin Reschke: Grateful for the Opportunity to Present Early Lab Data at EACR 2025
Opinion
Jun 20, 2025, 10:40
Arnaud Lallouette: ACT for Children - A Global Initiative to Tackle Inequities in Pediatric Cancer
Blog
Jun 20, 2025, 10:37
Sheraz Azhar: Day 1 at the Oncology Academy Masterclass – Breast Cancer: Moving Forward Together
Blog
Jun 20, 2025, 10:25
The Dorcas Cancer Foundation - Registration is Open for TDCF Survivor Webinar Series
Blog
Jun 20, 2025, 10:15
Aakash Desai Shares Review on HER2-Altered NSCLC and Emerging Targeted Strategies
Blog
Jun 20, 2025, 10:11
Alexandre Chan Was Awarded 2025 Susan and Henry Samueli COHS Faculty Assembly Basic Science COHS Team Research Award
Blog
Jun 20, 2025, 09:34
Stephen V Liu: Alexander Drilon at CIOT25 Clearly Favoring Taletrectinib as 1L for ROS1 NSCLC
Blog
Jun 20, 2025, 09:23
Aakash Desai Shared PLAN Study on Plasma-First NGS in Advanced NSCLC
Blog
Jun 20, 2025, 09:22
Jasmine Kamboj: Applications Are Now Open for 2026 CReDO Workshop for Training Researchers in Oncology